"Crypto Click Affiliate" – Brand New and Upcoming ASP Specialized in Cryptocurrency!We Provide Only Exceptional ICOs That Passed Our Strict Guidelines and Help Facilitate Fundraising for Technological Developments with Potential!
Crypto Click Limited has now started general affiliate registration for our ICO/cryptocurrency ASP “Crypto Click Affiliate” from 10th of November 2017.
“Crypto Click Affiliate” - ICO/cryptocurrency related ASP
Official Website: https://crypto-click.com/europa-member
- Concept of Crypto Click Affiliate
Our offered products are limited to cryptocurrency related products and affiliate commission will be paid out in Bitcoin.
ICOs (Initial Coin Offering) are attracting massive attention in the cryptocurrency industry at the moment.
ICOs are a way for start-up companies to raise money by selling investors tokens in exchange for equity, similar to an IPO.
ICO are booming with massive growth in the overall cryptocurrency
industry. To illustrate this, there was an ICO that raised 35mil USD
within 30sec, which was a big news in the industry.
Therefore “Crypto Click Affiliate” - the ICO and Cryptocurrency ASP - is the most attractive ASP, which provides our affiliates to earn massive commission with ICO products.
- Why ICO?
The ICO structure is very similar to an IPO.
If the tokens issued in the ICO was 1 USD as the starting price (for corporate fundraising), its price could go up to 2 USD, 3 USD and more when listed (=capital gain for investors).
This is the same effect as people investing in attractive unlisted stocks, more funds come into more attractive ICOs.
- Our mission is to serve our trusted affiliate partners with only exceptional ICOs. We believe this enables the advancement of technology, growth, and economic progress through our specialized affiliation program.
The growing popularity of ICOs in the global blockchain industry is due
to it being the newest way of corporate funding.
However, there are a number of incorrect information in circulation about ICOs.
Free flow of ICO information is not consistent, therefore purchaser can
receive inaccurate and twisted information causing big misunderstanding
of the white paper and the project itself.
ICO hosts providing accurate and detailed information for a deeper understanding of the project is the key to a successful fundraising.
Crypto Click Affiliate is here to provide the much needed true
information to our affiliates.
We will provide scheduled marketing material like ICO team interviews and IR information constantly.
Only exceptional ICOs that passed our strict guidelines are going to be our partners for their fundraising.
We have already lined up a number of credible ICO partners, mainly from Europe, through our extensive global network.
Please note that 4 of those amazing ICO partners are already in preparation and will soon be ready for their pre-sales.
And there are more and more of incredible ICO partners coming our way!
- Why Crypto Click Affiliate?
1. Life time commission
You can receive your commission permanently with Crypto Click Affiliate, unlike other affiliate systems.
In a general affiliate set up, affiliates earn their commission only
from their customer’s first product purchase.
In our affiliation program, our affiliates will receive commission on their customer’s every purchase without limitation.
The more the customers purchase, the bigger the commission, permanently.
2. High average spending per customer
We have data that shows average spending of a customer is around 2,630 USD.
Please remember that ICO customers are investors and their investment amount is increasing in speed with the hype of the ICO market.
3. 100% approval rate!
In general affiliation, ASP pays out commission only after advertisers approve sales of affiliates.
ASPs are therefore unable to pay out commissions to affiliates without having these approvals.
With this non-transparent system, advertisers have the power and could falsely adjust sales of affiliates.
At Crypto Click Affiliate, we are the only ones to review, confirm and
approve affiliate sales and not the advertisers.
With our innovative affiliation system, we can prevent the unfortunate losses of affiliate’s efforts.
4. Speedy 1 day commission payout
Speedy 1 day commission payout is now possible with these steps;
1. We send customer’s purchase amount to our payment solution system
2. We manage customer’s information within our system
3. We review, confirm and approve all the affiliate sales
4. We payout commission to our affiliates first
5. Finally we payout the rest to our ICO partners
Please note that on the first month of operation of our program, we will
run payouts in 2 week cycles.
By January 2018, we estimated to be able to provide you payouts within 1 day!
5. Hybrid commission program with affiliate commission & bounty
Crypto Click Affiliate introduces the new “Bounty Program” apart from the affiliate commissions.
Our affiliates can earn ICO tokens as a “bounty” reward, in exchange for media exposure on SNS, blogs and video-sharing sites.
We provide revenue share (affiliate commission) + media exposure
commission (bounty) as a new hybrid style of an ASP.
Please refer to below for our base reward program (please note that commission details will be adjusted for each ICO);
1. SNS Bounty
Twitter – Earn bounty by retweeting official ICO tweets five times.
Facebook – Earn bounty by providing “likes” and shares of official ICO posts.
2. Blog/Article post Bounty
Earn bounty by posting an article of the ICO’s whitepaper and road map.
3. Movie upload Bounty
Earn bounty by uploading original movies about ICO products.
Our affiliates can earn commission just by media exposure without actual
sales, which is great for affiliation beginners!
Use both of our attractive hybrid commission programs to maximize your earnings!
Hurry and join us on our brand new cryptocurrency affiliate program now!
“Crypto Click Affiliate”
- Crypto Click (Website: https://crypto-click.hk/europa-official)
Crypto Click is the operating company of Crypto Click Affiliate, our main business focus is to offer the best ICO/cryptocurrency affiliate program and the best solutions for ICO marketing, such as our ICO information curation service, blockchain installation support, and altcoin listing support at our partner’s exchange market.
For more information, please refer to our company website above.
Inquiry for Media
For further information, please contact us
Crypto Click Limited
Alice Chan, +852 98799568
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00 | Tiedote
Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba
ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11 | Tiedote
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06 | Tiedote
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo
Chugai Presents Results of Two Pivotal Phase lll Studies for its Bispecific Antibody HEMLIBRA® at WFH 201821.5.2018 12:44 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) today announced that full results from HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai’s hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. “The results from HAVEN 3 study demonstrate that HEMLIBRA, which was created with Chugai’s proprietary antibody engineering technologies, can reduce the bleeding risk in people with hemophilia A without inhibitors. The intra-patient comparison in this study also shows a statistically significant reduction in bleeding by HEMLIBRA prophylaxis compared to factor VIII therapy, the current stand
STATS Unveils STATS GPS, the Most Advanced Technology for Athlete Monitoring21.5.2018 10:00 | Tiedote
Today, STATS, the worldwide leader in sports data and intelligence, unveiled STATS GPS, an innovative system that uses a revolutionary 50-Hz sampling frequency to provide the most advanced real-time GPS technology available. STATS GPS allows teams to monitor player performance with customizable metrics like accelerations/decelerations, energy expenditure, count of zone entries, and time, distance and power thresholds. The innovative solution uses real 50-Hz sampling frequency and allows practitioners to monitor up to 100 players in real-time and post session with over 300 GPS, IMU and HR derived metrics. Embedded in the GPS vests are textile heart-rate sensors, making STATS GPS the most advanced technology on the market. “Teams and conditioning coaches need the latest technology to ensure players stay at peak health and fitness during long seasons,” said Ryan Paterson, Chief Global Officer at STATS. “With STATS GPS’ new 50-Hz technology, teams can instantly get performance information,
Sofinnova Partners Appoints Dr. Martin T. Rothman as Venture Partner21.5.2018 09:00 | Tiedote
Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners. As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme